BLACK DIAMOND THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $6.13 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-16
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-12-31 was $2.15M.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was $933.00K.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-06-30 was $396.00K.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-03-31 was $714.00K.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $6.13M, a 4.35% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $6.41M, a 24.36% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $8.47M, a 44.95% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $15.39M, a 34.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.13M 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $6.41M 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $8.47M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $15.39M 10-K · filed 2024-03-12 | |||
| 2021-12-31 | $11.44M 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.09M derived: sum of 2 quarters · filed 2022-03-17 | $3.48M derived: sum of 3 quarters · filed 2022-03-17 | $4.20M 10-K · filed 2022-03-17 |
| 2020-09-30 | $933.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.33M derived: sum of 2 quarters · filed 2020-11-10 | $2.04M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $1.11M 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $714.00K 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $319.00K 10-K · filed 2021-03-25 | |||
| 2018-12-31 | $7.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |